Shots:
- The P-II COMPARE study assessing SEL-212 (once monthly) vs pegloticase (twice monthly) in 170 patients with chronic refractory gout
- SEL-212 showed a numerically higher response rate on 1EP during 3 & 6 mos., but didn’t meet 1EP of superiority, higher response rate during 3 & 6mos., an overall reduction in mean SUA levels; patients with tophi at baseline showed higher responder rates with a reduction in mean SUA and is well tolerated
- SEL-212 is a combination product candidate designed to sustain control SUA levels in patients with chronic refractory gout, potentially reducing harmful tissue urate deposits. The companies also initiate the P-III studies (DISSOLVE I& II) of SEL-212 for chronic refractory gout with its expected results in H2’22 and BLA filing in Q3’23
Click here to read full press release/ article | Ref: PRNewswire | Image: Mynewsdesk
The post Sobi & Selecta Report Results of SEL-212 in P-II COMPARE Study for Chronic Refractory Gout first appeared on PharmaShots.
